The Japan Times - AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease

EUR -
AED 4.040333
AFN 71.510023
ALL 90.545728
AMD 393.646679
ANG 1.969726
AOA 1009.944764
ARS 1704.942344
AUD 1.631331
AWG 1.980285
AZN 1.871944
BAM 1.95355
BBD 2.214598
BDT 136.909225
BGN 1.951098
BHD 0.415222
BIF 3302.122259
BMD 1.100158
BND 1.417407
BOB 12.827345
BRL 6.363204
BSD 1.099509
BTN 103.220132
BWP 15.392274
BYN 3.30402
BYR 21563.098071
BZD 2.211402
CAD 1.573347
CDF 2546.865672
CHF 0.923863
CLF 0.027934
CLP 1099.421298
CNY 7.339979
CNH 7.332482
COP 3650.291454
CRC 489.98007
CUC 1.100158
CUP 26.388613
CVE 110.135666
CZK 24.415835
DJF 195.52023
DKK 7.475057
DOP 66.833035
DZD 150.764545
EGP 59.054505
ERN 16.502371
ETB 180.490389
FJD 2.508467
FKP 0.832333
GBP 0.834195
GEL 2.849455
GGP 0.832333
GHS 12.882282
GIP 0.832333
GMD 81.411633
GNF 9742.55914
GTQ 8.404283
GYD 230.085036
HKD 8.632016
HNL 29.572944
HRK 7.516241
HTG 144.114039
HUF 364.470283
IDR 20088.886264
ILS 3.568528
IMP 0.832333
INR 103.277504
IQD 1667.080201
IRR 2105413.743692
ISK 136.804598
JEP 0.832333
JMD 174.355252
JOD 0.780071
JPY 175.483461
KES 142.976254
KGS 96.208161
KHR 4508.848622
KMF 491.770673
KPW 990.142643
KRW 1469.217382
KWD 0.34282
KYD 0.916445
KZT 489.276552
LAK 24759.711927
LBP 98475.291572
LKR 365.968553
LRD 186.944716
LSL 18.633718
LTL 3.248481
LVL 0.665474
LYD 7.104657
MAD 10.961028
MDL 20.112838
MGA 5001.671816
MKD 61.529232
MMK 2309.857444
MNT 3965.001279
MOP 8.887066
MRU 44.652564
MUR 52.59871
MVR 16.939138
MWK 1906.804136
MXN 20.422267
MYR 4.504378
MZN 70.300755
NAD 18.633718
NGN 1479.954806
NIO 40.463403
NOK 10.611217
NPR 165.151812
NZD 1.998899
OMR 0.42301
PAB 1.099644
PEN 3.750181
PGK 5.020173
PHP 70.28635
PKR 304.055651
PLN 4.402002
PYG 6823.986472
QAR 4.01968
RON 5.346436
RSD 117.600302
RUB 90.870149
RWF 1624.529202
SAR 4.139941
SBD 8.908747
SCR 15.310077
SDG 661.743018
SEK 11.106145
SGD 1.418197
SHP 0.828401
SLE 25.358228
SLL 23069.768573
SOS 628.476251
SRD 41.244523
STD 22771.050732
STN 24.469041
SVC 9.621701
SYP 14304.25553
SZL 18.628125
THB 37.29701
TJS 10.133331
TMT 3.850553
TND 3.324272
TOP 2.648917
TRY 55.436932
TTD 7.467552
TWD 36.241956
TZS 2915.50032
UAH 49.985782
UGX 4563.226543
USD 1.100158
UYU 44.64757
UZS 13206.491383
VES 1004.311469
VND 28344.472383
VUV 132.810636
WST 3.092087
XAF 655.957
XAG 0.023431
XAU 0.00028599305
XCD 2.973232
XCG 1.981818
XDR 0.777869
XOF 655.957
XPF 119.331742
YER 260.242233
ZAR 18.690553
ZMK 9902.748037
ZMW 22.516275
ZWL 354.250448
SSP 6540.859064
MXV 2.291656
  • RYCEF

    0.1000

    19.81

    +0.5%

  • VOD

    -0.2500

    16.33

    -1.53%

  • CMSC

    -0.2800

    20.12

    -1.39%

  • RBGPF

    -2.0000

    65

    -3.08%

  • RIO

    -0.2500

    94.16

    -0.27%

  • BTI

    -1.2000

    54.85

    -2.19%

  • NGG

    -0.3000

    74.94

    -0.4%

  • GSK

    -0.3500

    49.35

    -0.71%

  • BCE

    -0.4200

    20.14

    -2.09%

  • CMSD

    -0.3400

    19.93

    -1.71%

  • BP

    -0.9100

    43.52

    -2.09%

  • RELX

    0.1700

    33.24

    +0.51%

  • BCC

    -0.6200

    75.97

    -0.82%

  • AZN

    -1.9400

    164.21

    -1.18%

  • JRI

    0.0000

    10.77

    0%

AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease

AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease

  • Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin

  • Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action

Text size:

VILNIUS, LT / ACCESS Newswire / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB).

AATec Medical and Northway Biotech Announce Partnership

Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system.

"With this partnership, we are establishing a robust and scalable production process for ATL- 105, laying the foundation for consistent quality for clinical development and commercial use," says Rüdiger Jankowsky, PhD, co-founder and CEO of AATec, and adds: "ATL-105 represents a new generation of inhaled biologics, combining anti-protease, anti-inflammatory, and antiinfective properties in one molecule. Delivered directly to the lungs, it enables fast, targeted action with minimal systemic exposure. We believe ATL-105 can redefine care in respiratory diseases with high medical need, such as non-CF bronchiectasis."

"We are excited to support AATec in progressing towards clinical trials", shares Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech. "AATec is advancing a promising therapeutic solution addressing significant unmet medical needs, supported by a highly capable and dedicated team. With our decades of expertise in microbial systems, we are well-positioned to scale this program efficiently and deliver quality at every step."

"We have recognized the opportunity to support a program that could meaningfully advance care for patients with respiratory diseases," adds André Markmann, PhD, VP of Business Development at Northway Biotech. "Inhaled protein therapies are gaining significant traction, and ATL-105 stands out as one of the most promising approaches in this area."

AATec develops ATL-105 to treat NCFB, a chronic inflammatory respiratory condition which affects millions of people worldwide. This debilitating disease is marked by dilated bronchi, persistent inflammation, frequent airway infections and impaired mucus clearance. In addition to NCFB, ATL-105 has therapeutic potential for a broader range of inflammatory and infectious respiratory diseases, such as COPD, ARDS and other indications, reflecting the versatility of its anti-inflammatory, immunomodulatory, and anti-infective properties.

About AATec Medical

AG AATec Medical GmbH is a biotechnology company developing a product platform based on a novel recombinant version of alpha-1 antitrypsin (AAT) for the treatment of respiratory inflammatory diseases, airway infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-ofconcept clinical trial with the first product candidate ATL-105 for inhaled application in non-CF bronchiectasis. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit https://www.aatec-medical.com/ and follow AATec on LinkedIn.

About Northway Biotech

Northway Biotech is a leading CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client's unique needs. For further information, please visit https://www.northwaybiotech.com.

Northway Biotech Contact:

Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
[email protected]

AATec Medical Contact:

Dr. Rüdiger Jankowsky, CEO
[email protected]

Media Contact:

MC Services
Katja Arnold, Julia von Hummel
[email protected]
Phone: +49 (0)89 2102280

SOURCE: Northway Biotech



View the original press release on ACCESS Newswire

K.Nakajima--JT